Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$144 Mln
P/E Ratio
--
P/B Ratio
0.67
Industry P/E
--
Debt to Equity
--
ROE
-0.46 %
ROCE
-39.51 %
Div. Yield
0 %
Book Value
3.13
EPS
-1.53
CFO
$-328.36 Mln
EBITDA
$-444.92 Mln
Net Profit
$-461.17 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
C4 Therapeutics Inc (CCCC)
| -43.06 | -35.53 | -49.38 | -77.04 | -55.95 | -- | -- |
|
BSE Sensex
| -3.77 | -0.92 | -6.67 | 3.66 | 9.18 | 19.75 | 10.11 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
C4 Therapeutics Inc (CCCC)
| -36.05 | -4.24 | -81.68 | -2.81 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.43 | 10,257.64 | 20.82 | 23.13 | |
| 33.74 | 13,384.89 | -- | -28.77 | |
| 109.59 | 11,042.16 | 33.66 | 14.16 | |
| 75.85 | 9,430.55 | 41.53 | 19.71 |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is... CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Address: 490 Arsenal Way, Watertown, MA, United States, 02472 Read more
CEO, President & Director
Mr. Andrew J. Hirsch M.B.A.
CEO, President & Director
Mr. Andrew J. Hirsch M.B.A.
Headquarters
Watertown, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of C4 Therapeutics Inc (CCCC) stood at -- as on 31-Dec-24
The share price of C4 Therapeutics Inc (CCCC) is $2.05 (NASDAQ) as of 18-Mar-2025 14:37 EDT. C4 Therapeutics Inc (CCCC) has given a return of -55.95% in the last 3 years.
C4 Therapeutics Inc (CCCC) has a market capitalisation of $ 144 Mln as on 17-Mar-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of C4 Therapeutics Inc (CCCC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the C4 Therapeutics Inc (CCCC) and enter the required number of quantities and click on buy to purchase the shares of C4 Therapeutics Inc (CCCC).
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Address: 490 Arsenal Way, Watertown, MA, United States, 02472
The CEO & director of Mr. Andrew J. Hirsch M.B.A.. is C4 Therapeutics Inc (CCCC), and CFO & Sr. VP is Mr. Andrew J. Hirsch M.B.A..
There is no promoter pledging in C4 Therapeutics Inc (CCCC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,168
|
|
|
1,141
|
|
|
1,072
|
|
|
1,045
|
| C4 Therapeutics Inc (CCCC) | Ratios |
|---|---|
|
Return on equity(%)
|
-45.58
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-295.96
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of C4 Therapeutics Inc (CCCC) was $0 Mln.
$-0.04
(
